B

Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315

Watchlist Manager
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Watchlist
Price: 8.25 HKD -2.02% Market Closed
Market Cap: 3.3B HKD
Have any thoughts about
Biocytogen Pharmaceuticals Beijing Co Ltd?
Write Note

Biocytogen Pharmaceuticals Beijing Co Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biocytogen Pharmaceuticals Beijing Co Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
B
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Other Long-Term Assets
ÂĄ59m
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Long-Term Assets
ÂĄ304.3m
CAGR 3-Years
-29%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Other Long-Term Assets
ÂĄ363.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Long-Term Assets
ÂĄ405.6m
CAGR 3-Years
39%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Long-Term Assets
ÂĄ1.2B
CAGR 3-Years
24%
CAGR 5-Years
38%
CAGR 10-Years
32%
Imeik Technology Development Co Ltd
SZSE:300896
Other Long-Term Assets
ÂĄ81.1m
CAGR 3-Years
29%
CAGR 5-Years
53%
CAGR 10-Years
N/A
No Stocks Found

Biocytogen Pharmaceuticals Beijing Co Ltd
Glance View

Market Cap
3.3B HKD
Industry
Biotechnology

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The company is headquartered in Beijing, Beijing. The company went IPO on 2022-09-01. The firm operates two business segments. The Drug Development Business segment is mainly engaged in the research and development of oncology and autoimmune disease treatments, as well as antibody development. The Preclinical Research Service segment is mainly engaged in gene editing, preclinical pharmacological efficacy evaluation and model animal sales.

Intrinsic Value
11.01 HKD
Undervaluation 25%
Intrinsic Value
Price
B

See Also

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Other Long-Term Assets?
Other Long-Term Assets
59m CNY

Based on the financial report for Dec 31, 2023, Biocytogen Pharmaceuticals Beijing Co Ltd's Other Long-Term Assets amounts to 59m CNY.

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 3Y
24%

Over the last year, the Other Long-Term Assets growth was 12%. The average annual Other Long-Term Assets growth rates for Biocytogen Pharmaceuticals Beijing Co Ltd have been 24% over the past three years .

Back to Top